Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)-Reference-Cited by-同舟云学术

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)

Published:2018-08-29 Issue:3 Volume:172 Page:603-610
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Shen Sherry,Unger Joseph M.,Crew Katherine D.,Till Cathee,Greenlee Heather,Gralow Julie,Dakhil Shaker R.,Minasian Lori M.,Wade James L.,Fisch Michael J.,Henry N. Lynn,Hershman Dawn L.^ORCID

Funder

National Cancer Institute

Breast Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4946-0/fulltext.html

Reference36 articles.

1. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462

2. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25(5):486–492

3. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570

4. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62

5. Mouridsen HT (2006) Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 22(8):1609–1621

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fast Facts and Concepts #483: Commonly Used Supplements for Cancer-Related Symptom Management;Journal of Palliative Medicine;2024-07-01

2. Update: Ausgewählte Nährstoffe in der onkologischen Intervention;Zeitschrift für Orthomolekulare Medizin;2024-07

3. Breast Cancer Management: The Role of Nutrition, Exercise and Psychosocial Well-being;Current Cancer Therapy Reviews;2024-03-11

4. A randomized controlled trial of hypnosis to manage musculoskeletal pain in breast cancer survivors taking aromatase inhibitors.;Psychology of Consciousness: Theory, Research, and Practice;2024-02-08

5. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial;Breast Cancer Research and Treatment;2024-01-27